文献速递血栓与止血贫血与红细胞疾病

转铁蛋白升高可预防楚瓦什红细胞增多症患者血栓形成

Increased transferrin protects from thrombosis in Chuvash erythrocytosis.
PubMed 文献 · Am J Hematol · 2023-07-12

研究纳入155例楚瓦什红细胞增多症患者和154例匹配对照,随访11年。患者基线转铁蛋白升高、铁蛋白降低,血栓风险为对照的8.9倍;促红细胞生成素升高与血栓风险相关,而转铁蛋白升高与血栓风险降低相关。EPO启动子SNP rs1617640的A等位基因与促红细胞生成素升高及血栓风险增加相关,TF内含子SNP rs3811647的A等位基因与转铁蛋白升高及血栓保护相关。

要点

  • 楚瓦什红细胞增多症患者基线转铁蛋白升高、铁蛋白降低。
  • 随访11年,患者血栓风险为对照的8.9倍。
  • 促红细胞生成素升高与血栓风险相关,转铁蛋白升高与血栓风险降低相关。

核心结论

  • 研究结果提示转铁蛋白升高与楚瓦什红细胞增多症患者血栓形成保护之间存在意外的因果关系。

研究设计与样本

  • 研究纳入155例楚瓦什红细胞增多症患者和154例匹配对照,在稳态下检测并随访血栓形成事件,随访11年。

主要发现

  • 患者基线转铁蛋白升高,铁蛋白降低。
  • VHLR200W纯合子和较低铁蛋白与较高的促红细胞生成素和转铁蛋白相关。
  • 随访11年期间,患者血栓风险为对照的8.9倍。
  • 促红细胞生成素升高与血栓风险相关,而血细胞比容或铁蛋白与血栓风险不相关。
  • 转铁蛋白升高与血栓风险降低相关,而非升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Von Hippel-Lindau protein (VHL) is essential to hypoxic regulation of cellular processes. VHL promotes proteolytic clearance of hypoxia-inducible transcription factors (HIFs) that have been modified by oxygen-dependent HIF-prolyl hydroxylases. A homozygous loss-of-function VHLR200W mutation causes Chuvash erythrocytosis, a congenital disorder caused by augmented hypoxia-sensing. Homozygous VHLR200W results in accumulation of HIFs that increase transcription of the erythropoietin gene and raise hematocrit. Phlebotomies reduce hematocrit and hyperviscosity symptoms. However, the major cause of morbidity and mortality in Chuvash erythrocytosis is thrombosis. Phlebotomies cause iron deficiency, which may further elevate HIF activity and transferrin, the HIF-regulated plasma iron transporter recently implicated in thrombogenesis. We hypothesized that transferrin is elevated in Chuvash erythrocytosis, and that iron deficiency contributes to its elevation and to thrombosis. We studied 155 patients and 154 matched controls at steady state and followed them for development of thrombosis. Baseline transferrin was elevated, and ferritin reduced in patients. VHLR200W homozygosity and lower ferritin correlated with higher erythropoietin and transferrin. During 11 years of follow-up, risk of thrombosis increased 8.9-fold in patients versus controls. Erythropoietin elevation, but not hematocrit or ferritin, correlated with thrombosis risk. Unexpectedly, transferrin elevation associated with reduced rather than increased thrombosis risk. The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients. Our findings suggest an unexpected causal relationship between increased transferrin and protection from thrombosis in Chuvash erythrocytosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Shah BN, Zhang X, Sergueeva AI, et al. Increased transferrin protects from thrombosis in Chuvash erythrocytosis. Am J Hematol. 2023. PMID: 37435906. doi:10.1002/ajh.27021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。